bisulfate


Also found in: Dictionary, Thesaurus, Medical.
Related to bisulfate: clopidogrel bisulfate, Sodium bisulfate

bisulfate

[bī′səl‚fāt]
(inorganic chemistry)
A compound that has the HSO4- radical; derived from sulfuric acid.
References in periodicals archive ?
The Sodium Bisulfate industry development trends and marketing channels are analyzed.
Chapter Four Sodium Bisulfate Production by Regions By Technology By Applications
For international and China market analysis, the report analyzes Clopidogrel Bisulfate Market in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of different types and applications, developments and trends of market, technology, competitive landscape, and leading suppliers' and countries' 2010-2015 capacity, production, cost, price, profit, production value, and gross margin.
For technical data and manufacturing plants analysis, the report analyzes Clopidogrel Bisulfate leading suppliers on capacity, commercial production date, manufacturing plants distribution, R&D status, technology sources, and raw materials sources.
Catalog of Produces on Base of Bisulfate of Molybdenum, Romanian Minister of Industry and Commerce, CNCAF MINVEST Deva, Branch of Stei, Romania.
The Court also ruled that Apotex's generic clopidogrel bisulfate infringes sanofi-aventis' patent, and has enjoined Apotex from marketing this product in the United States until the patent expires.
These risks and uncertainties include risks that may arise from the Department of Justice's criminal investigation on the Plavix(R) proposed settlement with Apotex, the adverse impact of Apotex's launch and generic product distributed into the market prior to the Court's injunction, the potential launch of a generic clopidogrel bisulfate product by other entities, as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward- Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2005.
Apotex) and the announcement on August 8, 2006 by Apotex that it had launched a generic clopidogrel bisulfate product that competes with PLAVIX(R).
These factors include, among other things, the unpredictability of the ultimate outcome of any litigation matter, including whether the appellate court in the Plavix litigation will, on appeal, rule in the company's favor and maintain interim relief pending trial, any risks associated with the criminal investigation conducted by the Department of Justice in connection with the proposed settlement with Apotex, and the launch of a generic clopidogrel bisulfate product by Apotex, including the amount of generic product distributed prior to the Court's injunction.
On August 8, 2006, Apotex announced that it had launched a generic version of clopidogrel bisulfate 75 mg tablets.
and the expiration of patents on certain other products, the impact on sales from amount of generic clopidigrel bisulfate on the market, and the impact and result of governmental investigations.
These risks and uncertainties include risks that may arise from the Department of Justice's criminal investigation on the Plavix(R) proposed settlement with Apotex, the risks related to the launch of a generic clopidogrel bisulfate product by Apotex, the potential launch of a generic clopidogrel bisulfate product by other entities, as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2005.